StockData

Nika Pharmaceuticals, Inc (NIKA) stock

NIKAOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 0/30
$0.41+0.00 (0.00%)

Close on Oct 16, 2026Market cap $431.19MP/E –Yield –

Nika Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Nika Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$78.14K. For fiscal 2025 it was -$76.40K. The highest annual figure on record is -$8.91K in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.40K–
FY2024Dec 31, 2024-$95.79K–
FY2023Dec 31, 2023-$64.83K–
FY2022Dec 31, 2022-$3.18M–
FY2021Dec 31, 2021-$14.71K–
FY2020Dec 31, 2020-$8.91K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.69K–
Q1 FY2026Mar 31, 2026-$13.36K–
Q4 FY2025Dec 31, 2025-$37.09K–
Q3 FY2025Sep 30, 2025-$8.00K–
Q2 FY2025Jun 30, 2025-$18.38K–
Q1 FY2025Mar 31, 2025-$12.95K–
Q4 FY2024Dec 31, 2024-$12.45K–
Q1 FY2024Mar 31, 2024-$45.95K–
Q4 FY2023Dec 31, 2023-$7.31K–
Q3 FY2023Sep 30, 2023-$10.14K–
Q2 FY2023Jun 30, 2023-$10.14K–
Q1 FY2023Mar 31, 2023-$19.57K-409.8%
Q4 FY2022Dec 31, 2022-$15.05K–
Q3 FY2022Sep 30, 2022-$6.34K–
Q2 FY2022Jun 30, 2022-$3.16M–
Q1 FY2022Mar 31, 2022$6.32K–
Q4 FY2021Dec 31, 2021-$3.30K–
Q3 FY2021Sep 30, 2021-$2.70K–
Q2 FY2021Jun 30, 2021-$2.96K–
Q1 FY2021Mar 31, 2021-$5.75K–
Q4 FY2020Dec 31, 2020-$8.75K–
Q3 FY2020Sep 30, 2020-$160–

More Nika Pharmaceuticals figures

See a number that looks wrong?